Introduction
Cardiac failure is a common clinical problem and the majority of patients with heart failure are more than 65 years old.'-4 Better treatment of heart failure in the elderly could therefore make a great impact (box 1).
Over the last decade, angiotensionconverting enzyme (ACE) inhibitors have established themselves in the treatment ofheart failure. Controlled trials5`7 show symptomatic improvement and increased exercise tolerance on chronic treatment (more than three months). The CONSENSUS study compared enalapril with placebo and demonstrated a reduction in one-year mortality from 52% to 31 %.1 The SOLVD study showed a 16% reduction in mortality at one year among enalapril-treated patients with less severe heart failure associated with systolic dysfunction.9 The SAVE study'0 and the AIRE study" established that the benefits of ACE-inhibitor therapy also apply to post-myocardial infarction patients with left ventricular dysfunction who were at risk of developing heart failure. These are important findings for a condition with such a poor prognosis.
Many of the studies cited above included some patients over 65 years of age but few have considered ACE-inhibitor therapy specifically in elderly people.'2-'7 The age of patients participating in large multicentre trials is lower than patients with heart failure in the community. There is some evidence that ACE inhibitors have a worse side-effect profile in the elderly'7 and the fear of hypotension and renal dysfunction in particular may hinder the use of Cardiac failure in the elderly * a common clinical problem becoming more common * increases in frequency with advancing agemost patients are over 65 years old * high mortality ACE-inhibitor therapy in elderly heart failure patients. For these reasons we only studied heart failure patients who were over 65 years of age.
Two studies comparing short-acting and long-acting ACE inhibitors suggested that the former cause less renal dysfunction.'8"9 It may be that a short-acting ACE inhibitor allows restoration of some angiotensin II at the end of each dose interval and that this protects the glomerular filtration rate (GFR).20 Our aim was therefore to compare the effects of low doses of captopril and enalapril on renal function in a group of elderly people with chronic cardiac failure.
Subjects and methods
This was a six-month double-blind, group comparative study of captopril (12.5 mg, bid) versus enalapril (2.5 mg bid). Six centres were involved in recruitment. Inclusion and exclusion criteria for the study population are shown in box 2.
At their first visit, patients were assessed for their suitability to join the study and after full explanation gave their written consent. The study was approved by the ethics committees of all centres involved. Baseline assessments included: haemodynamic measurements (lying and standing blood pressure and pulse); blood tests (urea, creatinine and electrolytes, liver function tests, glucose, full blood count); standard 12-lead electrocardiogram (ECG); postero-anterior chest X-ray; exercise test; and administration of a symptom-oriented questionnaire.
There followed a run-in period of up to two weeks when each patient took a placebo capsule twice daily. A second set of baseline assessments was performed within a week of the first visit and this included measurement of GFR. This was measured using a single injection, three blood sample radio isotope clearance technique,2' the radio isotope being 99mTcDTPA at one centre and 51 CrEDTA at the other centres. In addition, iodohippurate measurement of effective renal plasma flow was performed by three centres.
Entry criteria for study population The walking test was performed in 25 patients from one centre, by asking them to walk an individually selected distance and the time taken to perform this was measured using a stopwatch. This had previously been validated by a pilot study in 10 fit and 20 frail elderly people.
In one centre an interviewer administered a symptom-oriented questionnaire to assess quality of life and minor adverse effects. This had also been validated by a pilot study in 10 fit and 20 frail elderly people.
The distribution of all the variables studied were assessed for normality and differences between the treatment groups were tested by analysis of variance with treatment and centre as factors or by using permutation tests22 as appropriate. Formal comparisons between the treatment groups for symptom profiles and adverse events were carried out using either chi-square or Fisher's exact test. Confidence intervals were two-tailed. Differences were accepted as statistically significant at the 5% level of probability. Measurements for GFR were corrected for body surface area using the standard equation.
Results
A total of 96 patients from six centres entered the placebo run-in phase of the study; 16 were ineligible, thus 80 patients were randomised to active treatment. The characteristics of the patients studied are shown in table 1. There were no significant differences between the two treatment groups in any of the baseline features. A further 24 patients were withdrawn during the study for the reasons shown in table 2. They were included in the analysis until the point at which they were withdrawn from the study.
GFR
Measurements of GFR are summarised in Furthermore the doses of both drugs that were used were higher than in present clinical practice. Giles et al'9 found that the longer acting agent, lisinopril, caused a rise in serum creatinine in more patients than captopril. It has been suggested that the longer acting agents, such as enalapril and lisinopril, may be more likely to adversely affect renal function than captopril, which is short-acting, as they do not allow the renin-angiotensin system to recover between doses.
In our study, we used 'gold standard' methods to measure GFR, not just serum creatinine. There was a tendency for GFR to improve in patients taking captopril and deteriorate in those taking enalapril, although the differences between the drugs were not statistically significant. Significantly more patients on enalapril had more than a 10% fall in GFR compared with those on captopril. These findings are consistent with previous studies. However, since the baseline figures for GFR in the enalapril patients were higher than those on captopril, it is possible that the slightly larger numbers of patients showing a fall in GFR on enalapril could be seen as a regression towards the mean. This encouraging renal profile may have partly been due to using lower dosages of both ACE inhibitors. It may also have been because we only measured GFR after three months treatment, by which time improvement in cardiac function would have compensated for any deterioration in renal function during the first week of treatment.
First-dose hypotension is a particularly important adverse event in the elderly. Hyponatraemia as an important risk factor for first-dose hypotension (30 times the risk if Na' < 130 mmol/1).27 In elderly patients with stable chronic heart failure, the first dose of captopril produced an early (1.5 h) brief fall in blood pressure; the first dose of enalapril reduced blood pressure later (4-10 h) and for longer.28 Although the initiation of ACEinhibitor therapy caused large falls in systolic blood pressure in many patients, few had any associated symptoms. There was no significant difference between the ACE inhibitors in the magnitude of blood pressure reduction.
The fact that three patients taking enalapril had late onset symptomatic hypotension after three days of treatment which was noticed when they either fell or their mobility deteriorated indicates the importance of early Cardiac failure in the elderly McLay et aP9 found that some patients had a large fall in blood pressure after their fourth dose of captopril whereas they had only a small reduction in blood pressure after the first dose, suggesting that this adverse reaction can occur with both short-and long-acting drugs.
Conclusion
The most important and clinically relevant conclusion from this study was that both ACE inhibitors were well tolerated in elderly patients with chronic heart failure. There was no significant difference between their effects on mean GFR. However, there was an increased risk of deterioration in GFR in patients taking enalapril, although this could have been due to the higher initial value in the enalapril group. The first doses of drugs were well tolerated despite hypotension being common. The reasons for the late-onset hypotension observed in three patients are not entirely clear but clinicians should be aware that this may happen. Thus, the differences between the two ACE inhibitors were marginal. Captopril does offer the advantage that it may be easier to monitor patients for shorter periods of time after giving the first dose. 
